Inhibiting the hypoxia response for cancer therapy: the new kid on the block.
The hypoxia-inducible transcription factor (HIF)-1alpha inhibitor KC7F2 described in this issue of Clinical Cancer Research is the newest addition to an emerging class of antitumor agents targeting the hypoxia response. Here, we discuss the proposed mechanism of action of KC7F2 and its potential strengths and limitations in comparison with other promising HIF-1alpha inhibitors.
Koh
Mei Yee
MY
Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas, USA.
Spivak-Kroizman
Taly R
TR
Powis
Garth
G
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015687:Cell Hypoxia / Q000502:physiology; D004220:Disulfides / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods*; D004354:Drug Screening Assays, Antitumor / Q000639:trends; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D013449:Sulfonamides / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004220:Disulfides; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; C545729:KC7F2 compound; D013449:Sulfonamides